Ultime notizie per Pasofino Gold (OTC:EFRGF) Azioni

Pasofino Gold Ltd is a Canada-based gold exploration company. It is engaged in the business of acquisition, exploration, and development of mineral properties located in Quebec, Canada. The company's projects consist of the Dugbe Gold Project in Liberia.

Pasofino Gold Ltd

Biotech

News

General

CING

Cingulate Announces Efficacy Results From Phase 3 Pediatric Study of CTx-1301 In ADHD Showing Improvement Of ADHD Symptoms At Week 5

Constituting one of the members of the Magnificent 7, social media giant Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) needs no introduction. Thanks to a market capitalization exceeding $1.61 trillion, its influence stretches across the globe. At the same time, the performance of META stock this year has paled in comparison to prior years, setting the stage for a tight battle between the bulls and bears.
Fundamentally, Meta Platforms continues to deliver impressive financial results. For example, in the fourth quarter of 2024, the company<a href="https://www.benzinga.com/quote/META"> posted ad revenue</a> of $46.8 billion, marking a year-over-year increase of approximately 21%. For the full year, total revenue landed at $164.5 billion, up 22% against 2023's tally.
Even better, it's difficult to imagine another enterprise being in a position to challenge Meta's<a href="https://www.benzinga.com/insights/news/25/05/45496844/investigating-meta-platformss-standing-in-interactive-media-amp-services-industry-compared-to-compe"> competitive moat</a> anytime soon. As the largest social media company in the world, Meta boasts close to 4 billion monthly active users worldwide. In addition, the tech juggernaut features a "Family of Apps" – Facebook, Instagram, Messenger and WhatsApp. Subsequently, the platform holistically resonates with consumers from multiple age groups.
Still, not everyone is convinced that META stock represents good value. According to investor Peter Lynch's<a href="https://www.benzinga.com/25/05/45500627/only-3-mag-7-stocks-pass-peter-lynchs-favorite-valuation-test-tesla-isnt-one-of-them"> favorite valuation test</a> – the price-earnings-to-growth (PEG) ratio – only three names among the Magnificent 7 come close to being reasonably priced. Unfortunately, with META's PEG ratio landing at 2.48, its valuation stretches the definition of "reasonable."
Adding to the skepticism, Cathie Wood-led Ark Invest recently caught Wall Street's attention for making significant transactions. Conspicuously, the fund reduced its holdings of META stock, a decision which coincides with the tech firm's ongoing legal battles. One particularly contentious issue involves Meta's efforts to dismiss an antitrust case filed by the Federal Trade Commission (FTC) — part of a trial that could<a href="https://www.benzinga.com/tech/25/05/45485147/meta-pleads-with-judge-to-dismiss-ftcs-antitrust-case-in-high-stakes-trial"> potentially lead to the breakup</a> of the tech behemoth.
The Direxion ETFs: With both sides carrying ample ammunition for their narratives, financial services provider Direxion offers contrasting META-focused exchange-traded funds for speculators to trade. Those in the bullish camp may consider the Direxion Daily META Bull 2X Shares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/METU#NASDAQ">METU</a>). On the other end, pessimists may be interested in the Direxion Daily META Bear 1X Shares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/METD#NASDAQ">METD</a>).
Primarily, the METU and METD ETFs offer a convenient medium for speculation. Typically, those interested in leverage or short wagers must engage the options market, an arena known for its myriad complexities. These Direxion funds, however, act much like any other publicly traded security – therefore, the learning curve is relatively shallow.
Still, investors should be aware of the unique risks of leveraged and inverse ETFs. First, these products tend to be more volatile than standard funds. Second, they're meant for exposure lasting no longer than one day. Holding either METU or METD beyond the recommended period may incur value decay due to the daily compounding effect.
The METU ETF: After a choppy start to the year, the METU ETF is attempting to build a rising baseline, having gained over 5% since the January opener.
<ul class="wp-block-list">
<li>METU recently secured an important technical victory by shooting above its 50-day moving average.</li>
<li>Technically, its next natural target is the psychologically significant $40 level. Over the longer term, the bulls will eventually need to secure the $44 price tag.</li>
</ul>
<figure class="wp-block-image"><img loading="lazy" decoding="async" width="1032" height="622" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/20080506/image-245.png" alt="" class="wp-image-921126" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/20080506/image-245.png 1032w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/20080506/image-245-300x181.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/20080506/image-245-1024x617.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/20080506/image-245-768x463.png 768w" sizes="(max-width: 1032px) 100vw, 1032px" /></figure>
The METD ETF: Although the METD ETF saw positive momentum throughout March and most of April, a market recovery in May has translated into hefty losses for the inverse fund.
<ul class="wp-block-list">
<li>Currently, METD finds itself trading below its 50 and 200 DMAs, indicative of significant demand loss.</li>
<li>What bearish speculators need to watch closely is the fading volume for the inverse fund, which may suggest reduced interest in the short thesis.</li>
</ul>
<figure class="wp-block-image"><img loading="lazy" decoding="async" width="1027" height="627" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/20080506/image-245.png" alt="" class="wp-image-921127" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/20080506/image-245.png 1027w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/20080506/image-245-300x181.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/20080506/image-245-1024x617.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/20080506/image-245-768x463.png 768w" sizes="(max-width: 1027px) 100vw, 1027px" /></figure>
Featured image by <a href="https://pixabay.com/users/lobostudiohamburg-13838/?utm_source=link-attribution&amp;utm_medium=referral&amp;utm_campaign=image&amp;utm_content=292994">Thomas Ulrich</a> from <a href="https://pixabay.com/photos/phone-display-apps-applications-292994/">Pixabay</a>.

Long Ideas

Short Ideas

Technicals

Trading Ideas

ETFs

METD

METU

Meta Platforms' Valuation Debate Sets The Stage For Direxion's Bull And Bear Funds

IHS Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHS#NYSE">IHS</a>) reported quarterly earnings of $0.10 per share which missed the analyst consensus estimate of $0.12 by 16.67 percent. This is a 121.28 percent increase over losses of $(0.47) per share from the same period last year. The company reported quarterly sales of $439.60 million which beat the analyst consensus estimate of $413.42 million by 6.33 percent. This is a 5.23 percent increase over sales of $417.74 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

IHS Holding Q1 EPS $0.10 Misses $0.12 Estimate, Sales $439.60M Beat $413.42M Estimate

Barclays analyst Theresa Chen maintains DT Midstream (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DTM#NYSE">DTM</a>) with a Equal-Weight and raises the price target from $102 to $103.

Price Target

Analyst Ratings

Barclays Maintains Equal-Weight on DT Midstream, Raises Price Target to $103

Multi-year agreement with longstanding customer highlights Cognyte&#39;s growing success in expanding adoption of AI-powered solutions
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cognyte.com%2F&amp;esheet=54256833&amp;newsitemid=20250520351476&amp;lan=en-US&amp;anchor=Cognyte+Software+Ltd.&amp;index=1&amp;md5=a42ddb8c20496fd2c9df74d3ffb58918">Cognyte Software Ltd.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNT#NASDAQ">CGNT</a>) (&quot;Cognyte&quot;), a global leader in software-driven technology for investigative analytics, today announced a new three-year subscription agreement valued at over&nbsp;$10 million&nbsp;annually with a longstanding national security customer in the EMEA region. Under the new agreement, the agency will gain access to Cognyte&#39;s latest AI-powered capabilities, an expanded suite of solutions and continuous enhancements going forward. The subscription approach enables faster adoption of innovation, greater operational agility and ensures the agency stays ahead of evolving threats.
As part of the new agreement, the agency will upgrade to the latest version of Cognyte&#39;s investigative analytics solution, strengthening its ability to address complex and evolving security challenges. The platform enables the agency to generate actionable intelligence from vast and diverse data sources, so they can accelerate investigations, improve decision making and increase operational success.
&quot;We&#39;re proud to deepen our relationship with this longstanding customer as they modernize their investigative operations through a more agile, innovation-driven model,&quot; said Efi Nuri, Chief Revenue Officer at Cognyte. &quot;This agreement demonstrates both the value of Cognyte&#39;s AI-powered solutions and our ability to drive recurring revenue through high-value subscription partners.&quot;

Contracts

CGNT

Cognyte Receives $10M+ Annual 3-Year Subscription Agreement With National Security Agency

Needham analyst Serge Belanger reiterates Trevi Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVI#NASDAQ">TRVI</a>) with a Buy and maintains $24 price target.

Reiteration

TRVI

Needham Reiterates Buy on Trevi Therapeutics, Maintains $24 Price Target

Mineralys Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLYS#NASDAQ">MLYS</a>), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced that data from the pivotal Phase 3 Launch-HTN trial evaluating the efficacy and safety of lorundrostat for the treatment of uncontrolled hypertension (uHTN) or resistant hypertension (rHTN) will be presented in a late-breaking clinical trials session at the 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025), which will be held in Milan at the MICO Congress Center, on May 23-26, 2025.

MLYS

Mineralys Therapeutics To Present Data From Pivotal Phase 3 Launch-HTN Trial Evaluating Efficacy And Safety Of Lorundrostat For Treatment Of uHTN Or rHTN In Late-Breaking Clinical Trials Session At ESH 2025

LOBO

LOBO EV Technologies Expands Partnership With Serbian Distributor; Distributor Now Committed To Sourcing ~$5M Annually In CKD Mode Directly From LOBO

Barclays analyst Adrienne Yih maintains Bath &amp; Body Works (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>) with a Equal-Weight and raises the price target from $31 to $35.

BBWI

Barclays Maintains Equal-Weight on Bath & Body Works, Raises Price Target to $35

ProPhase Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.18) by 27.78 percent. This is a 59.38 percent increase over losses of $(0.32) per share from the same period last year. The company reported quarterly sales of $1.43 million which missed the analyst consensus estimate of $2.45 million by 41.59 percent. This is a 60.62 percent decrease over sales of $3.63 million the same period last year.

PRPH

ProPhase Labs Q1 EPS $(0.13) Beats $(0.18) Estimate, Sales $1.43M Miss $2.45M Estimate

<ul>
<li>Red Hat and AMD power leading-edge AI inference performance with vLLM on AMD Instinct&trade; GPUs</li>
<li>Red Hat OpenShift Virtualization on AMD EPYC&trade; CPUs helps organizations more easily modernize existing systems for future innovations</li>
</ul>
Red Hat, the world&#39;s leading provider of open source solutions, and AMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) today announced a strategic collaboration to propel AI capabilities and optimize virtualized infrastructure. With this deepened alliance, Red Hat and AMD will expand customer choice across the hybrid cloud, from deploying optimized, efficient AI models to more cost-effectively modernizing traditional virtual machines (VMs).
As workload demand and diversity continue to rise with the introduction of AI, organizations must have the capacity and resources to meet these escalating requirements. The average datacenter, however, is dedicated primarily to traditional IT systems, leaving little room to support intensive workloads such as AI. To answer this need, Red Hat and AMD are bringing together the power of Red Hat&#39;s industry-leading open source solutions with the comprehensive portfolio of AMD high-performance computing architectures.
AMD and Red Hat: Driving to more efficient generative AI
Red Hat and AMD are combining the power of&nbsp;<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.redhat.com%2Fen%2Fproducts%2Fai&amp;esheet=54257337&amp;newsitemid=20250520085545&amp;lan=en-US&amp;anchor=Red+Hat+AI&amp;index=1&amp;md5=f10c55db7eb643fa83a471ec7287685f">Red Hat AI</a>&nbsp;with the AMD portfolio of x86-based processors and GPU architectures to support optimized, cost-efficient and production-ready environments for AI-enabled workloads.
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.amd.com%2Fen%2Fproducts%2Faccelerators%2Finstinct.html&amp;esheet=54257337&amp;newsitemid=20250520085545&amp;lan=en-US&amp;anchor=AMD+Instinct+GPUs&amp;index=2&amp;md5=ac807e2e2b61148558871c04c28ea81d">AMD Instinct GPUs</a>&nbsp;are now fully enabled on&nbsp;<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.redhat.com%2Fen%2Fproducts%2Fai%2Fopenshift-ai&amp;esheet=54257337&amp;newsitemid=20250520085545&amp;lan=en-US&amp;anchor=Red+Hat+OpenShift+AI&amp;index=3&amp;md5=334b84f531ef5b12ebe990ae2a681be7">Red Hat OpenShift AI</a>, empowering customers with the high-performing processing power necessary for AI deployments across the hybrid cloud without extreme resource requirements. In addition, using&nbsp;<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.amd.com%2Fen%2Fproducts%2Faccelerators%2Finstinct%2Fmi300%2Fmi300x.html&amp;esheet=54257337&amp;newsitemid=20250520085545&amp;lan=en-US&amp;anchor=AMD+Instinct+MI300X+GPUs&amp;index=4&amp;md5=643e571ef366484d7b84fab77b168549">AMD Instinct MI300X GPUs</a>&nbsp;with&nbsp;<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.redhat.com%2Fen%2Fproducts%2Fai%2Fenterprise-linux-ai&amp;esheet=54257337&amp;newsitemid=20250520085545&amp;lan=en-US&amp;anchor=Red+Hat+Enterprise+Linux+AI&amp;index=5&amp;md5=3ff86edccd0c017b460e8b2cc659f4ec">Red Hat Enterprise Linux AI</a>, Red Hat and AMD conducted testing on Microsoft Azure ND MI300X v5 to successfully demonstrate AI inferencing for scaling small language models (SLMs) as well as large language models (LLM) deployed across multiple GPUs on a single VM, reducing the need to deploy across multiple VMs and reducing performance costs.
To drive further performance acceleration and tuning capabilities, Red Hat and AMD are collaborating in the upstream&nbsp;<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.redhat.com%2Fen%2Ftopics%2Fai%2Fwhat-is-vllm&amp;esheet=54257337&amp;newsitemid=20250520085545&amp;lan=en-US&amp;anchor=vLLM+community&amp;index=6&amp;md5=2b19ee89d1f5ce76332e357aa6a40547">vLLM community</a>&nbsp;to foster more efficient AI inference. With this upstream activation, Red Hat and AMD aim to deliver:
<ul>
<li>Improved performance on AMD GPUs:&nbsp;By upstreaming the AMD kernel library and optimizing various components like the Triton kernel and FP8, Red Hat and AMD are advancing inference performance for both dense and quantized models, enabling faster and more efficient execution of vLLM on AMD Instinct MI300X accelerators.</li>
<li>Enhanced multi-GPU support:&nbsp;Improving collective communication and optimizing multi-GPU workloads opens the door to more scalable and energy-efficient AI deployments, which is particularly beneficial for workloads that require distributed computing across multiple GPUs, reducing bottlenecks and improving overall throughput.</li>
<li>Expanded vLLM ecosystem engagement:&nbsp;Cross-collaboration between Red Hat, AMD and other industry leaders like IBM helps accelerate upstream development to propel continuous improvements for both the vLLM project and AMD GPU optimization, further benefiting vLLM users that rely on AMD hardware for AI inference and training.</li>
</ul>

Red Hat And AMD Enters Strategic Collaboration Expanding Customer Choice For AI And Virtualization Across The Hybrid Cloud

During the last three months, 8 analysts shared their evaluations of Entegris (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTG#NASDAQ">ENTG</a>), revealing diverse outlooks from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Entegris and provided 12-month price targets. The average target is $104.88, accompanied by a high estimate of $130.00 and a low estimate of $85.00. Highlighting a 13.59% decrease, the current average has fallen from the previous average price target of $121.38. 
<img src="https://www.benzinga.com/files/images/story/2025/1747742529_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A comprehensive examination of how financial experts perceive Entegris is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Charles Shi</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Atif Malik</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$102.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Timothy Arcuri</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$85.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Aleksey Yefremov</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$117.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Charles Shi</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$100.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Timothy Arcuri</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Michael Harrison</td>
<td>Seaport Global</td>
<td>Lowers</td>
<td>Buy</td>
<td>$115.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Aleksey Yefremov</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$130.00</td>
<td>$141.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Entegris. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Entegris compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Entegris's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ENTG/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Entegris analyst ratings.</a>
<h2>Get to Know Entegris Better</h2>
Entegris Inc is a supplier of materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include The Materials Solutions segment which provides materials-based solutions, such as chemical vapor and atomic layer deposition materials, chemical mechanical planarization slurries and pads, ion implantation specialty gases, formulated etch and clean materials, and other specialty materials. The Advanced Purity Solutions segment offers filtration, purification and contamination-control solutions that improve customers' yield, device reliability and cost by ensuring the purity of critical liquid chemistries and gases and the cleanliness of wafers and other substrates.
<h3>Financial Insights: Entegris</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Entegris's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 0.29%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.
Net Margin: Entegris's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 8.13%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Entegris's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 1.69%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Entegris's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.75% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Entegris's debt-to-equity ratio stands notably higher than the industry average, reaching 1.08. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>The Basics of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ENTG

8 Analysts Assess Entegris: What You Need To Know

Analysts' ratings for Life360 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIF#NASDAQ">LIF</a>) over the last quarter vary from bullish to bearish, as provided by 6 analysts.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $57.17, with a high estimate of $70.00 and a low estimate of $48.00. Marking an increase of 4.9%, the current average surpasses the previous average price target of $54.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1747742510_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The perception of Life360 by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maria Ripps</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$70.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Chris Kuntarich</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$57.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Rob Sanderson</td>
<td>Loop Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$58.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Mark Kelley</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$48.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Andrew Boone</td>
<td>Citizens Capital Markets</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$55.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Andrew Boone</td>
<td>Citizens Capital Markets</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$55.00</td>
<td>$55.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Life360. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Life360 compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Life360's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Life360's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/LIF/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Life360 analyst ratings.</a>
<h2>About Life360</h2>
Life360 is the world's largest family-focused social network, with over 50 million monthly active users. Security-conscious families use the Life360 app to track each other's whereabouts and to track the location of their pets and personal belongings. Life360 also offers a suite of additional security features, such as driver safety monitoring, roadside assistance, and emergency dispatching. In the US, the Life360 app regularly ranks in the top 10 most popular social-networking apps and in the top 25 across all apps in terms of daily active users.
<h3>Life360: Delving into Financials</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Life360's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 32.47%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Life360's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.22% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Life360's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 1.19%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Life360's ROA excels beyond industry benchmarks, reaching 0.98%. This signifies efficient management of assets and strong financial health.
Debt Management: Life360's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.0.
<h2>Analyst Ratings: What Are They?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing Life360: Insights From 6 Financial Analysts

Preconditioning with lymphodepletion linked to stronger MAR-T cells response and suggests enhanced anti-tumor activity
Highest enrollment since study launch underscores momentum and signals a positive trial trajectory
Clinical data readout from Phase 1 APOLLO study expected later this year
HOUSTON, May 20, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRKR#NASDAQ">MRKR</a>), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today reported scientific evidence from the Phase 1 APOLLO study demonstrating that lymphodepletion improves the expansion and persistence of MAR-T cells.
The Company's Phase 1 APOLLO study is investigating MT-601, a MAR-T cell product, in patients with lymphoma who have relapsed after anti-CD19 chimeric antigen receptor (CAR)-T cell therapy or for whom anti-CD19 CAR-T cell therapy is not an option. In December, the Company provided an update on the progress and clinical observations from the study, with a data cutoff date of September 10, 2024 (<a href="https://www.globenewswire.com/Tracker?data=L6Jp4KSWxv6KBGnQv1wvI6EQHPNttVIROljIdyCnDf1FEahhJN7SYAq_E5WCWvTxk44dyc0TTAKFl3yPNomKKqavpEMsrHlcLOR2wXRx1QkFpC9Hz-EyIGuXJy2YlW6bRTeX2AHr5gzGbZ29fB5xcJu6mIHN5WXsJQCHpDVSAhHVBbdwDXFjbO8DH9iCIK5ybLej0Ph19BZd46Iyo2sFi7glM_Yh3-4-TQLcXwH5GYVsgeMZvLiei4dha30gi3ob">Press Release, December 19, 2024</a>). This update included clinical data from 9 patients from 5 clinical sites in the United States. Infusion of MT-601 was well tolerated in all study participants with no dose limiting toxicities (DLTs), including immune-effector cell associated neurotoxicity syndrome (ICANS). Objective responses were achieved in 7 out of 9 patients (78%), with 4 patients demonstrating complete response (CR; 44.4%) as early as 4 weeks after infusion of MT-601.
The Company previously reported that study participants showed early objective responses with and without lymphodepletion. Today, Marker provides data demonstrating preliminary evidence that lymphodepletion supports the expansion and persistence of MT-601 in vivo. Using T Cell Receptor (TCR) sequencing as an immunomonitoring strategy, the Company has evidence suggesting that MT-601 MAR-T cell clones in the drug product expanded and persisted at significantly higher levels in patients receiving lymphodepletion compared to patients who did not undergo the conditioning regimen. Preliminary results from this observation have been posted on the Investor Relations section of the <a href="https://www.globenewswire.com/Tracker?data=DEEVHSm3qDFSgas3DAon1Q68TVu-1Ssr5geDo_4RHoFxhGrDlMVXkchiG-fwYNOsa6Rp56wxicljJSQeqRFhJthHFaoJdi_JMm406CmdsqgMlUBpfHbqG4gAAjf6E9U2vODkHyfz2uP3W9pg_1LNqQ==">Marker website</a>.
The Company believes that the enhanced in vivo expansion and persistence of MT-601 may positively influence the clinical anti-tumor activity of MT-601 in the ongoing APOLLO study. Similar correlations have been observed when using lymphodepletion with other T cell therapies, including CAR-T and tumor infiltrating lymphocyte (TIL) products. While these prior studies have shown that T cell therapies can be effective with and without lymphodepletion, the use of lymphodepletion was associated with improved clinical outcomes and an enhanced expansion and persistence of T cells (Rosenberg SA, J Natl Cancer Inst, 1994; Ramos CA et al, J Clin Oncol, 2020; Turtle CJ et al, Sci Transl Med, 2016).
Driven by encouraging early clinical data and a shifting competitive landscape, the Company today announced a marked increase in patient enrollment. In the first five months of 2025 alone, the Company enrolled and successfully manufactured product for more patients than in the entire year of 2024. This upward trend reflects growing momentum and is expected to meaningfully expand the magnitude of the clinical data set, which the Company plans to present later this year.

MRKR

Marker Therapeutics Reports Scientific Evidence From Phase 1 APOLLO Study Demonstrating That Lymphodepletion Improves Expansion And Persistence Of MAR-T Cells

Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on CytomX Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTMX#NASDAQ">CTMX</a>) in the last three months.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $4.38, along with a high estimate of $5.00 and a low estimate of $2.50. Witnessing a positive shift, the current average has risen by 11.17% from the previous average price target of $3.94.
<img src="https://www.benzinga.com/files/images/story/2025/1747742462_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of CytomX Therapeutics among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$5.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Joseph Catanzaro</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$5.00</td>
<td>$2.50</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$5.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Joseph Catanzaro</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$2.50</td>
<td>$3.25</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to CytomX Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of CytomX Therapeutics compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of CytomX Therapeutics's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of CytomX Therapeutics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/CTMX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on CytomX Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Delving into CytomX Therapeutics's Background</h2>
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
<h3>CytomX Therapeutics: Financial Performance Dissected</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: CytomX Therapeutics's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 22.8%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: CytomX Therapeutics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 46.2%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 191.31%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): CytomX Therapeutics's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 21.48%, the company showcases efficient use of assets and strong financial health.
Debt Management: CytomX Therapeutics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.33.
<h2>Analyst Ratings: What Are They?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CTMX

CytomX Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

In the preceding three months, 17 analysts have released ratings for Home Depot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>), presenting a wide array of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">11</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $429.88, a high estimate of $455.00, and a low estimate of $391.00. Highlighting a 3.79% decrease, the current average has fallen from the previous average price target of $446.82. 
<img src="https://www.benzinga.com/files/images/story/2025/1747742449_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A comprehensive examination of how financial experts perceive Home Depot is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$455.00</td>
<td>$455.00</td>
</tr>
<tr>
<td>Zachary Fadem</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$420.00</td>
<td>$445.00</td>
</tr>
<tr>
<td>Scot Ciccarelli</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$393.00</td>
<td>$391.00</td>
</tr>
<tr>
<td>Christopher Horvers</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$410.00</td>
<td>$470.00</td>
</tr>
<tr>
<td>Simeon Gutman</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$410.00</td>
<td>$450.00</td>
</tr>
<tr>
<td>Scot Ciccarelli</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$391.00</td>
<td>$437.00</td>
</tr>
<tr>
<td>Peter Keith</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$418.00</td>
<td>$435.00</td>
</tr>
<tr>
<td>Laura Champine</td>
<td>Loop Capital</td>
<td>Lowers</td>
<td>Buy</td>
<td>$430.00</td>
<td>$465.00</td>
</tr>
<tr>
<td>Peter Benedict</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$430.00</td>
<td>$440.00</td>
</tr>
<tr>
<td>Peter Keith</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$435.00</td>
<td>$455.00</td>
</tr>
<tr>
<td>Steven Shemesh</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$424.00</td>
<td>$431.00</td>
</tr>
<tr>
<td>Steven Forbes</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Buy</td>
<td>$450.00</td>
<td>$450.00</td>
</tr>
<tr>
<td>Seth Basham</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$440.00</td>
<td>$440.00</td>
</tr>
<tr>
<td>Scot Ciccarelli</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$437.00</td>
<td>$467.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$455.00</td>
<td>$455.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$455.00</td>
<td>$455.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$455.00</td>
<td>$455.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Home Depot. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Home Depot compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Home Depot's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Home Depot's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/HD/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Home Depot analyst ratings.</a>
<h2>Unveiling the Story Behind Home Depot</h2>
Home Depot is the world's largest home improvement specialty retailer, operating more than 2,300 warehouse-format stores offering more than 30,000 products in store and 1 million products online in the US, Canada, and Mexico. Its stores offer building materials, home improvement products, lawn and garden products, and decor products and provide various services, including home improvement installation services and tool and equipment rentals. The acquisition of Interline Brands in 2015 allowed Home Depot to enter the MRO business, which has been expanded through the tie-up with HD Supply (2020). The additions of the Company Store brought textiles to the lineup, and the 2024 tie-up with SRS will help grow professional demand in roofing, pool and landscaping projects.
<h3>Home Depot: Delving into Financials</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Home Depot displayed positive results in 3M. As of 31 January, 2025, the company achieved a solid revenue growth rate of approximately 14.14%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Consumer Discretionary sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Home Depot's net margin excels beyond industry benchmarks, reaching 7.55%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Home Depot's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 48.24% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Home Depot's ROA stands out, surpassing industry averages. With an impressive ROA of 3.1%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 9.38, caution is advised due to increased financial risk.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Home Depot: 17 Analysts Share Their Views

Westlake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLK#NYSE">WLK</a>) underwent analysis by 26 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">7</td>
<td align="right">7</td>
<td align="right">12</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $114.38, a high estimate of $166.00, and a low estimate of $76.00. This current average has decreased by 14.74% from the previous average price target of $134.15. 
<img src="https://www.benzinga.com/files/images/story/2025/1747742438_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A clear picture of Westlake's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Sison</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$76.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Charles Neivert</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$100.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Neel Kumar</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$98.00</td>
<td>$122.00</td>
</tr>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$96.00</td>
<td>$122.00</td>
</tr>
<tr>
<td>Duffy Fischer</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$95.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Jeffrey Zekauskas</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$82.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>John McNulty</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$103.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Michael Sison</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$95.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Michael Leithead</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$100.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Peter Osterland</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$117.00</td>
<td>$132.00</td>
</tr>
<tr>
<td>Steve Byrne</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$103.00</td>
<td>$116.00</td>
</tr>
<tr>
<td>Peter Osterland</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$132.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Michael Sison</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$110.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Joshua Spector</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$127.00</td>
<td>$144.00</td>
</tr>
<tr>
<td>Charles Neivert</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$105.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Patrick Cunningham</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$116.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Peter Osterland</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$155.00</td>
<td>$166.00</td>
</tr>
<tr>
<td>Charles Neivert</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$120.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Jeffrey Zekauskas</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$110.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$133.00</td>
<td>$147.00</td>
</tr>
<tr>
<td>Neel Kumar</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$122.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>John McNulty</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$132.00</td>
<td>$157.00</td>
</tr>
<tr>
<td>Peter Osterland</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$166.00</td>
<td>$168.00</td>
</tr>
<tr>
<td>Michael Sison</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$130.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Steve Byrne</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$116.00</td>
<td>$134.00</td>
</tr>
<tr>
<td>Michael Leithead</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$135.00</td>
<td>$175.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Westlake. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Westlake compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Westlake's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Westlake's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/WLK/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Westlake analyst ratings.</a>
<h2>Get to Know Westlake Better</h2>
Westlake Corp is a manufacturer and supplier of chemicals, polymers, and building products. Its Performance and Essential Materials segment offers a wide range of essential building blocks for making products utilized in everyday living, including olefins, vinyl chemicals, polyethylene, and epoxies. Its Housing and Infrastructure Products segment produces key finished goods for building products, pipe and fittings, and global compounds businesses.
<h3>Westlake: A Financial Overview</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Challenges: Westlake's revenue growth over 3M faced difficulties. As of 31 March, 2025, the company experienced a decline of approximately -4.34%. This indicates a decrease in top-line earnings. When compared to others in the Materials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Westlake's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -1.41% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Westlake's ROE excels beyond industry benchmarks, reaching -0.38%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Westlake's ROA excels beyond industry benchmarks, reaching -0.19%. This signifies efficient management of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.53, Westlake adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Basics of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Westlake Stock: Analyst Perspectives (26 Ratings)

Ionis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONS#NASDAQ">IONS</a>) has been analyzed by 14 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">9</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $53.86, a high estimate of $70.00, and a low estimate of $39.00. Experiencing a 7.01% decline, the current average is now lower than the previous average price target of $57.92. 
<img src="https://www.benzinga.com/files/images/story/2025/1747742416_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The analysis of recent analyst actions sheds light on the perception of Ionis Pharmaceuticals by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$50.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Debjit Chattopadhyay</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$64.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$50.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$55.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Announces</td>
<td>Buy</td>
<td>$45.00</td>
<td>-</td>
</tr>
<tr>
<td>Joshua Smith</td>
<td>Redburn Atlantic</td>
<td>Announces</td>
<td>Neutral</td>
<td>$39.00</td>
<td>-</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$45.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$47.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>David Lebowitz</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$64.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$70.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Kostas Biliouris</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$45.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Ionis Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Ionis Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Ionis Pharmaceuticals's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Ionis Pharmaceuticals's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/IONS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Ionis Pharmaceuticals analyst ratings.</a>
<h2>Unveiling the Story Behind Ionis Pharmaceuticals</h2>
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
<h3>Understanding the Numbers: Ionis Pharmaceuticals's Finances</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Ionis Pharmaceuticals displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 10.14%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Ionis Pharmaceuticals's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -111.64% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Ionis Pharmaceuticals's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -27.62%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Ionis Pharmaceuticals's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -5.05%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Ionis Pharmaceuticals's debt-to-equity ratio is notably higher than the industry average. With a ratio of 2.96, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

IONS

Expert Outlook: Ionis Pharmaceuticals Through The Eyes Of 14 Analysts

GDS Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDS#NASDAQ">GDS</a>) affirms FY2025 sales outlook from $1.55 billion-$1.59 billion to $1.55 billion-$1.59 billion vs $11.48 billion estimate.

Guidance

GDS Holdings Affirms FY2025 Sales Guidance of $1.55B-$1.59B vs $11.48B Est

Telsey Advisory Group analyst Joseph Feldman maintains Home Depot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>) with a Outperform and maintains $455 price target.

Telsey Advisory Group Maintains Outperform on Home Depot, Maintains $455 Price Target

Press Releases

Pasofino Gold Announces Management Changes

Pasofino Gold Completes Drilling at 'Bukon Jedeh', Dugbe Gold Project in Liberia

How Does Pasofino Gold's Dugbe Gold Project Shape Up Against Competitors?

West Africa Has Long Had A Wealth Of Gold Resources – Companies Are Now Looking To Regions Like Liberia For Their As-Yet Untapped Potential

Pasofino Gold: Unlocking Liberia's Untapped Gold Potential

Pasofino Gold Enters Into Exclusive Agreement For $75 Million Cash Acquisition Offer

How Pasofino Gold Is Leveraging Gold Potential In Mining-Friendly Liberia Through Its Scalable Project

What Makes Liberia Ideal For Gold Mining?

AMSYF

EFRGF

HUMRF

LGDTF

TSX:OSI

TSXV:VEIN

Pasofino Gold

ENFORCER GOLD CORP by Enforcer Gold Corp.

Screenshot 2025-04-28 at 7.36.54 PM

Commodities

Markets

ENFORCER GOLD CORP ORD by Enforcer Gold Corp.

Getting In On Gold: Mining In Mineral-Rich West Africa With Pasofino Gold

Screenshot 2025-04-15 at 5.32.05 PM

Following Takeover Of Parent Company, Pasofino Inks Cooperation Deal With Investors, Calls It &#34;Rebirth&#34; Of West African Gold Project

Screenshot 2025-01-21 at 6.56.21 PM

TSXV:V

Screenshot 2025-01-17 at 6.47.56 PM

Screenshot 2024-09-23 at 5.37.26 PM

Screenshot 2024-08-27 at 5.49.46 PM

Pasofino Gold: Unlocking Liberia&#39;s Untapped Gold Potential

Screenshot 2024-07-02 at 8.11.40 AM

West Africa Has Long Had A Wealth Of Gold Resources – Companies Are Now Looking To Countries Like Liberia For Their Great Potential

Screenshot 2024-06-27 at 5.36.01 PM

How Does Pasofino Gold&#39;s Dugbe Gold Project Shape Up Against Competitors?

Comments

Pasofino Gold

Notizie

Ultime notizie per Pasofino Gold (OTC:EFRGF) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO